"Researchers are embarking on an ambitious project to construct human genetic material from scratch," reports the Guardian, "to learn more about how DNA works and pave the way for the next generation of medical therapies." Scientists on the Synthetic Human Genome (SynHG) project will spend the next five years developing the tools and knowhow to build long sections of human genetic code in the lab. These will be inserted into living cells to understand how the code operates.

Armed with the insights, scientists hope to devise radical new therapies for the treatment of diseases. Among the possibilities are living cells that are resistant to immune attack or particular viruses, which could be transplanted into patients with autoimmune diseases or with liver damage from chronic viral infections. "The information gained from synthesising human genomes may be directly useful in generating treatments for almost any disease," said Prof Jason Chin, who is leading the project at the MRC's Laboratory of Molecular Biology (LMB) in Cambridge...

For the SynHG project, researchers will start by making sections of a human chromosome and testing them in human skin cells. The project involves teams from the universities of Cambridge, Kent, Manchester, Oxford and Imperial College London... Embedded in the project is a parallel research effort into the social and ethical issues that arise from making genomes in the laboratory, led by Prof Joy Zhang at the University of Kent. "We're a little way off having anything tangible that can be used as a therapy, but this is the time to start the discussion on what we want to see and what we don't want to see," said Dr Julian Sale, a group leader at the LMB.

"A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes," reports the New York Times.

"One year later, these 10 patients no longer need insulin. The other two patients need much lower doses." The experimental treatment, called zimislecel and made by Vertex Pharmaceuticals of Boston, involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. The new islet cells were infused and reached the pancreas, where they took up residence. The study was presented Friday evening at the annual meeting of the American Diabetes Association and published online by The New England Journal of Medicine...

Patients in the study began to need less insulin within a few months of being infused with new islet cells, and most stopped needing the hormone altogether at about six months [said Dr. Trevor Reichman, director of the pancreas and islet transplant program at University Health Network, a hospital in Toronto, and first author of the study]. He added that patients' episodes of hypoglycemia went away within the first 90 days of treatment.

If the study continues to show positive results, the company expects to submit an application to the FDA next year. "For the short term, this looks promising" for severely affected patients like those in the study," said Dr. Irl B. Hirsch, a diabetes expert at the University of Washington who was not involved in the study. But patients in the trial had to stay on drugs to prevent the immune system from destroying the new cells. Suppressing the immune system, he said, increases the risk of infections and, over the long term, can increase the risk of cancer... Patients may have to take the immunosuppressant drugs for the rest of their lives, the Vertex spokesperson said.

Longtime Slashdot reader fahrbot-bot shares a report from the Cool Down: A team of chemical engineers at the Massachusetts Institute of Technology has invented a new process to separate crude oil components, potentially bringing forward a replacement that can cut its harmful carbon pollution by 90%. The original technique, which uses heat to separate crude oil into gasoline, diesel, and heating oil, accounts for roughly 1% of all global energy consumption and 6% of dirty energy pollution from the carbon dioxide it releases.

"Instead of boiling mixtures to purify them, why not separate components based on shape and size?" said Zachary P. Smith, associate professor of chemical engineering at MIT and senior author of the study, as previously reported in Interesting Engineering. The team invented a polymer membrane that divides crude oil into its various uses like a sieve. The new process follows a similar strategy used by the water industry for desalination, which uses reverse osmosis membranes and has been around since the 1970s. [The membrane excelled in lab tests. It increased the toluene concentration by 20 times in a mixture with triisopropylbenzene. It also effectively separated real industrial oil samples containing naphtha, kerosene, and diesel.]

Space may be the perfect place to study cancer — and someday even treat it," writes Space.com: On Earth, gravity slows the development of cancer because cells normally need to be attached to a surface in order to function and grow. But in space, cancer cell clusters can expand in all directions as bubbles, like budding yeast or grapes, said Shay Soker, chief science program officer at Wake Forest's Institute for Regenerative Medicine. Since bubbles grow larger and more quickly in space, researchers can more easily test substances clinging to the edge of the larger bubbles, too. Scientists at the University of Notre Dame are taking advantage of this quirk to develop an in-space cancer test that needs just a single drop of blood. The work builds on a series of bubble-formation experiments that have already been conducted on the ISS. "If cancer screening using our bubble technology in space is democratized and made inexpensive, many more cancers can be screened, and everyone can benefit," said Tengfei Luo, a Notre Dame researcher who pioneered the technology, speaking to the ISS' magazine, Upward. "It's something we may be able to integrate into annual exams. It sounds far-fetched, but it's achievable...."

Chemotherapy patients could save precious time, too. In normal gravity, they typically have to spend a half-hour hooked up to a needle before the medicine begins to take effect, because most drugs don't dissolve easily in water. But scientists at Merck have discovered that, in space, their widely used cancer drug pembrolizumab, or Keytruda, can be administered through a simple injection, because large crystalline molecules that would normally clump together are suspended in microgravity... Someday, microgravity could even help patients recovering from surgery heal faster than they would on Earth, Soker added. "Wound healing in high pressure is faster. That's the hyperbaric treatment for wounds...."

For the Wake Forest experiment, which is scheduled to launch next spring, scientists will cut out two sections of a cancer tumor from around 20 patients. One sample will stay on Earth while the other heads to the ISS, with scientists observing the difference. The testing will be completed within a week, to avoid any interference from cosmic radiation. If successful, Soker said, it could set the stage for diagnostic cancer tests in space available to the general population — perhaps on a biomedical space station that could launch after the planned demise of the ISS. "Can we actually design a special cancer space station that will be dedicated to cancer and maybe other diseases?" Shoker asked, answering his question in the affirmative. "Pharmaceutical companies that have deep pockets would certainly support that program."

Anne Wojcicki, co-founder of 23andMe, has regained control of the bankrupt DNA-testing company after a nonprofit she controls outbid Regeneron Pharmaceuticals with a $305 million offer. The company filed for bankruptcy in March due to declining demand and fallout from a major 2023 data breach.

"The agreement with non-profit TTAM Research Institute is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals," the company said in a statement.

Since filing for bankruptcy in March, 23andMe has received data deletion requests from 1.9 million users -- around 15% of its customer base. That number was revealed by 23andMe's interim chief executive Joseph Selsavage during a House Oversight Committee hearing, during which lawmakers scrutinized the company's sale following an earlier bankruptcy auction. "The bankruptcy sparked concerns that the data of millions of Americans who used 23andMe could end up in the hands of an unscrupulous buyer, prompting customers to ask the company to delete their data," adds TechCrunch. From the report: Pharmaceutical giant Regeneron won the court-approved auction in May, offering $256 million for 23andMe and its banks of customers' DNA and genetic data. Regeneron said it would use the 23andMe data to aid the discovery of new drugs, and committed to maintain 23andMe's privacy practices. Truly deleting your personal genetic information from the DNA testing company is easier said than done. But if you were a 23andMe customer and are interested, MIT Technology Review outlines that steps you can take.

It's no longer a hypothetical question, writes the Washington Post. "In recent years, scientists have devised powerful genetic tools that may be able to eradicate mosquitoes and other pests once and for all."

But along with the ability to fight malaria, dengue, West Nile virus and other serious diseases, "the development of this technology also raises a profound ethical question: When, if ever, is it okay to intentionally drive a species out of existence...?" When so many wildlife conservationists are trying to save plants and animals from disappearing, the mosquito is one of the few creatures that people argue is actually worthy of extinction. Forget about tigers or bears; it's the tiny mosquito that is the deadliest animal on Earth. The human misery caused by malaria is undeniable. Nearly 600,000 people died of the disease in 2023, according to the World Health Organization, with the majority of cases in Africa... But recently, the Hastings Center for Bioethics, a research institute in New York, and Arizona State University brought together a group of bioethicists to discuss the potential pitfalls of intentionally trying to drive a species to extinction. In a policy paper published in the journal Science last month, the group concluded that "deliberate full extinction might occasionally be acceptable, but only extremely rarely..."

It's unclear how important malaria-carrying mosquitoes are to broader ecosystems. Little research has been done to figure out whether frogs or other animals that eat the insects would be able to find their meals elsewhere. Scientists are hotly debating whether a broader "insect apocalypse" is underway in many parts of the world, which may imperil other creatures that depend on them for food and pollination... Instead, the authors said, geneticists should be able to use gene editing, vaccines and other tools to target not the mosquito itself, but the single-celled Plasmodium parasite that is responsible for malaria. That invisible microorganism — which a mosquito transfers from its saliva to a person's blood when it bites — is the real culprit.
A nonprofit research consortium called Target Malaria has genetically modified mosquitoes in their labs (which get core funding from the Gates Foundation and from Open Philanthropy, backed by Facebook co-founder Dustin Moskovitz and his wife). ), and hopes to deploy them in the wild within five years...

An anonymous reader quotes a report from IEEE Spectrum: In a development straight out of science fiction, Australian startup Cortical Labs has released what it calls the world's first code-deployable biological computer. The CL1, which debuted in March, fuses human brain cells on a silicon chip to process information via sub-millisecond electrical feedback loops. Designed as a tool for neuroscience and biotech research, the CL1 offers a new way to study how brain cells process and react to stimuli. Unlike conventional silicon-based systems, the hybrid platform uses live human neurons capable of adapting, learning, and responding to external inputs in real time. "On one view, [the CL1] could be regarded as the first commercially available biomimetic computer, the ultimate in neuromorphic computing that uses real neurons," says theoretical neuroscientist Karl Friston of University College London. "However, the real gift of this technology is not to computer science. Rather, it's an enabling technology that allows scientists to perform experiments on a little synthetic brain."

The first 115 units will begin shipping this summer at $35,000 each, or $20,000 when purchased in 30-unit server racks. Cortical Labs also offers a cloud-based "wetware-as-a-service" at $300 weekly per unit, unlocking remote access to its in-house cell cultures. Each CL1 contains 800,000 lab-grown human neurons, reprogrammed from the skin or blood samples of real adult donors. The cells remain viable for up to six months, fed by a life-support system that supplies nutrients, controls temperature, filters waste, and maintains fluid balance. Meanwhile, the neurons are firing and interpreting signals, adapting from each interaction.

The CL1's compact energy and hardware footprint could make it attractive for extended experiments. A rack of CL1 units consumes 850-1,000 watts, notably lower than the tens of kilowatts required by a data center setup running AI workloads. "Brain cells generate small electrical pulses to communicate to a broader network," says Cortical Labs Chief Scientific Officer Brett Kagan. "We can do something similar by inputting small electrical pulses representing bits of information, and then reading their responses. The CL1 does this in real time using simple code abstracted through multiple interacting layers of firmware and hardware. Sub-millisecond loops read information, act on it, and write new information into the cell culture." The company sees CL1 as foundational for testing neuropsychiatric treatments, leveraging living cells to explore genetic and functional differences. "It allows people to study the effects of stimulation, drugs and synthetic lesions on how neuronal circuits learn and respond in a closed-loop setup, when the neuronal network is in reciprocal exchange with some simulated world," says theoretical neuroscientist Karl Friston of University College London. "In short, experimentalists now have at hand a little 'brain in a vat,' something philosophers have been dreaming about for decades."

There was excitement when biotech company Collosal announced genetically modified grey wolves (first hailed as a "de-extinction" of the Dire wolf species after several millennia). "But bioethicists and conservationists are expressing unease with the kind of scientific research," writes the Chicago Tribune. [Alternate URL here.] "Unfortunately, as clever as this science is ... it's can-do science and not should-do science," said Lindsay Marshall, director of science in animal research at Humane World for Animals, formerly the Humane Society of the U.S.... Ed Heist, a professor at Southern Illinois University and a conservation geneticist, said the news bothered him. "This is not conservation, but people conflate it," he said. "The point is entertainment...."

Naomi Louchouarn [program director of wildlife partnerships at Humane World for Animals], has dedicated her studies and research to the relationship between humans and animals, specifically carnivores like gray wolves. "The reason our current endangered species are becoming extinct is because we don't know how to coexist with them," she said. "And this doesn't solve that problem at all." Humans can treat the symptoms of wildlife conflict with "big, flashy silver bullets" and "in this case, advanced, inefficient science," she said, but the real solution is behavioral change. "Assuming that we could actually bring back a full population of animals," Louchouarn said, "which is so difficult and so crazy — that's a big if — I don't understand the point of trying to bring back a woolly mammoth when we already can't coexist with elephants."
The article notes that even Colossal's chief science officer says their technology is at best one of several tools for fighting biodiversity loss, calling it a battle which humans are 'not close to winning'... We as a global community need to continue to invest in traditional approaches to conservation and habitat preservation, as well as in the protection of living endangered species."

But the article adds that the Trump administration "is citing the case of the dire wolf as it moves to reduce federal protections under the Endangered Species Act of 1973." (Wednesday U.S. interior secretary Doug Burgum has even posted on X "The concept of 'de-extinction' can serve as a bedrock for modern species conservation.")

And the article adds that "During a livestreamed town hall with Interior Department employees on April 9, Burgum said: "If we're going to be in anguish about losing a species, now we have an opportunity to bring them back. Pick your favorite species and call up Colossal. Ken Angielczyk, curator of mammal fossils at the Field Museum who researches extinct species that lived 200 to 300 million years ago, said it's a misguided approach. "If that's the basis ... for changing regulations related to the endangered species list, that is very, very premature," he said. "Because we can't resurrect things.... If the purpose is to restore the damage to the shared ecosystem, we have that opportunity right now," she said. "And that's the necessity immediately...."

"This whole idea that extinction is reversible is so dangerous," Marshall said, "because then it stops us caring."
Thanks to long-time Slashdot reader walterbyrd for sharing the news.

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. WSJ: Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to bolster manufacturing in the U.S., while barring companies from working with Chinese biotech suppliers, the National Security Commission on Emerging Biotechnology said in a report Tuesday. To achieve its goals, the federal government and U.S.-based researchers will also need to work with allies and partners around the world.

"China is quickly ascending to biotechnology dominance, having made biotechnology a strategic priority for 20 years," the commission said. Without prompt action, the U.S. risks "falling behind, a setback from which we may never recover." The findings convey the depth of worry in Washington that China's rapid biotechnology advances jeopardize U.S. national security. Yet translating the concern into tangible actions could prove challenging.

[...] China plays a large role supplying drug ingredients and even some generic medicines to the U.S. For years, it produced copycat versions of drugs developed in the West. Recent years have seen it become a formidable hub of biotechnology innovation, after the Chinese government gave priority to the field as a critical sector in China's efforts to become a scientific superpower.

An anonymous reader quotes a report from 404 Media: The creator of an open source genetic database is shutting it down and deleting all of its data because he has come to believe that its existence is dangerous with "a rise in far-right and other authoritarian governments" in the United States and elsewhere. "The largest use case for DTC genetic data was not biomedical research or research in big pharma," Bastian Greshake Tzovaras, the founder of OpenSNP, wrote in a blog post. "Instead, the transformative impact of the data came to fruition among law enforcement agencies, who have put the genealogical properties of genetic data to use."

OpenSNP has collected roughly 7,500 genomes over the last 14 years, primarily by allowing people to voluntarily submit their own genetic information they have downloaded from 23andMe. With the bankruptcy of 23andMe, increased interest in genetic data by law enforcement, and the return of Donald Trump and rise of authoritarian governments worldwide, Greshake Tzovaras told 404 Media he no longer believes it is ethical to run the database. "I've been thinking about it since 23andMe was on the verge of bankruptcy and been really considering it since the U.S. election. It definitely is really bad over there [in the United States]," Greshake Tzovaras told 404 Media. "I am quite relieved to have made the decision and come to a conclusion. It's been weighing on my mind for a long time."

Greshake Tzovaras said that he is proud of the OpenSNP project, but that, in a world where scientific data is being censored and deleted and where the Trump administration has focused on criminalizing immigrants and trans people, he now believes that the most responsible thing to do is to delete the data and shut down the project. "Most people in OpenSNP may not be at particular risk right now, but there are people from vulnerable populations in here as well," Greshake Tzovaras said. "Thinking about gender representation, minorities, sexual orientation -- 23andMe has been working on the whole 'gay gene' thing, it's conceivable that this would at some point in the future become an issue." "Across the globe there is a rise in far-right and other authoritarian governments. While they are cracking down on free and open societies, they are also dedicated to replacing scientific thought and reasoning with pseudoscience across disciplines," Greshake Tzovaras wrote. "The risk/benefit calculus of providing free & open access to individual genetic data in 2025 is very different compared to 14 years ago. And so, sunsetting openSNP -- along with deleting the data stored within it -- feels like it is the most responsible act of stewardship for these data today."

"The interesting thing to me is there are data preservation efforts in the U.S. because the government is deleting scientific data that they don't like. This is approaching that same problem from a different direction," he added. "We need to protect the people in this database. I am supportive of preserving scientific data and knowledge, but the data comes second -- the people come first. We prefer deleting the data."

An anonymous reader shared this report from the Mercury News: After a year of fastidious planning, a microscopic sample of the ultra-rare radioactive element berkelium arrived at a Berkeley Lab. With just 48 hours to experiment before it would become unusable, a group of nearly 20 researchers focused intently on creating a brand-new molecule. Using a chemical glove box, a polycarbonate glass box with protruding gloves that shields substances from oxygen and moisture, scientists combined the berkelium metal with an organic molecule containing only carbon and hydrogen to create a chemical reaction... [Post-doc researcher Dominic] Russo, researcher Stefan Minasian, and 17 other scientists at Lawrence Berkeley National Laboratory had created berkelocene, a new molecule that usurps theorists' expectations about how carbon bonds with heavy-metal elements.

In the future, berkelocene may help humanity safely dispose of nuclear waste, according to a study published in the academic journal Science... The new molecular structure is, in the nomenclature of researchers, a "sandwich." In this formation, a berkelium atom, serving as the filling, lays in between two 8-membered carbon rings — the "bread" — and resembles an atomic foot-long sub. "It has this very symmetric geometry, and it's the first time that that's been observed," Minasian said.
The researchers believe more accurate models for how actinide elements like uranium behave will help solve problems related to long-term nuclear waste storage.

In an op-ed for MIT Technology Review, authors Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi make the case for human "bodyoids" that could reduce animal testing, improve drug development, and alleviate organ shortages: Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation so long? These challenges stem in large part from a common root cause: a severe shortage of ethically sourced human bodies. It may be disturbing to characterize human bodies in such commodifying terms, but the unavoidable reality is that human biological materials are an essential commodity in medicine, and persistent shortages of these materials create a major bottleneck to progress.

This imbalance between supply and demand is the underlying cause of the organ shortage crisis, with more than 100,000 patients currently waiting for a solid organ transplant in the US alone. It also forces us to rely heavily on animals in medical research, a practice that can't replicate major aspects of human physiology and makes it necessary to inflict harm on sentient creatures. In addition, the safety and efficacy of any experimental drug must still be confirmed in clinical trials on living human bodies. These costly trials risk harm to patients, can take a decade or longer to complete, and make it through to approval less than 15% of the time.

There might be a way to get out of this moral and scientific deadlock. Recent advances in biotechnology now provide a pathway to producing living human bodies without the neural components that allow us to think, be aware, or feel pain. Many will find this possibility disturbing, but if researchers and policymakers can find a way to pull these technologies together, we may one day be able to create "spare" bodies, both human and nonhuman. These could revolutionize medical research and drug development, greatly reducing the need for animal testing, rescuing many people from organ transplant lists, and allowing us to produce more effective drugs and treatments. All without crossing most people's ethical lines.

Although it may seem like science fiction, recent technological progress has pushed this concept into the realm of plausibility. Pluripotent stem cells, one of the earliest cell types to form during development, can give rise to every type of cell in the adult body. Recently, researchers have used these stem cells to create structures that seem to mimic the early development of actual human embryos. At the same time, artificial uterus technology is rapidly advancing, and other pathways may be opening to allow for the development of fetuses outside of the body. Such technologies, together with established genetic techniques to inhibit brain development, make it possible to envision the creation of "bodyoids" -- a potentially unlimited source of human bodies, developed entirely outside of a human body from stem cells, that lack sentience or the ability to feel pain.

An anonymous reader quotes a report from 404 Media: 23andMe filed for Chapter 11 bankruptcy Sunday, leaving the fate of millions of people's genetic information up in the air as the company deals with the legal and financial fallout of not properly protecting that genetic information in the first place. The filing shows how dangerous it is to provide your DNA directly to a large, for-profit commercial genetic database; 23andMe is now looking for a buyer to pull it out of bankruptcy. 23andMe said in court documents viewed by 404 Media that since hackers obtained personal data about seven million of its customers in October 2023, including, in some cases "health-related information based upon the user's genetics," it has faced "over 50 class action and state court lawsuits," and that "approximately 35,000 claimants have initiated, filed, or threatened to commence arbitration claims against the company." It is seeking bankruptcy protection in part to simplify the fallout of these legal cases, and because it believes it may not have money to pay for the potential damages associated with these cases.

CEO and cofounder Anne Wojcicki announced she is leaving the company as part of this process. The company has the genetic data of more than 15 million customers. According to its Chapter 11 filing, 23andMe owes money to a host of pharmaceutical companies, pharmacies, artificial intelligence companies (including a company called Aganitha AI and Coreweave), as well as health insurance companies and marketing companies. Shortly before the filing, California Attorney General Rob Bonta issued an "urgent" alert to 23andMe customers: "Given 23andMe's reported financial distress, I remind Californians to consider invoking their rights and directing 23andMe to delete their data and destroy any samples of genetic material held by the company."

In a letter to customers Sunday, 23andMe said: "Your data remains protected. The Chapter 11 filing does not change how we store, manage, or protect customer data. Our users' privacy and data are important considerations in any transaction, and we remain committed to our users' privacy and to being transparent with our customers about how their data is managed." It added that any buyer will have to "comply with applicable law with respect to the treatment of customer data."

404 Media's Jason Koebler notes that "there's no way of knowing who is going to buy it, why they will be interested, and what will become of its millions of customers' DNA sequences. 23andMe has claimed over the years that it strongly resists law enforcement requests for information and that it takes customer security seriously. But the company has in recent years changed its terms of service, partnered with big pharmaceutical companies, and, of course, was hacked."

An anonymous reader quotes a report from Ars Technica: [A] team of Korean researchers [describe] how they've engineered a bacterial strain that can make a useful polymer starting with nothing but glucose as fuel. The system they developed is based on an enzyme that the bacteria use when they're facing unusual nutritional conditions, and it can be tweaked to make a wide range of polymers. The researchers focused on the system bacterial cells use for producing polyhydroxyalkanoates (PHAs). These chemicals are formed when the bacterial cells continue to have a good supply of carbon sources and energy, but they lack some other key nutrients needed to grow and divide. Under these circumstances, the cell will link together small molecules that contain a handful of carbons, forming a much larger polymer. When nutritional conditions improve, the cell can simply break down the polymer and use the individual molecules it contained.

The striking thing about this system is that it's not especially picky about the identity of the molecules it links into the polymer. So far, over 150 different small molecules have been found incorporated into PHAs. It appears that the enzyme that makes the polymer, PHA synthase, only cares about two things: whether the molecule can form an ester bond (PHAs are polyesters), and whether it can be linked to a molecule that's commonly used as an intermediate in the cell's biochemistry, Coenzyme A. Normally, PHA synthase forms links between molecules that run through an oxygen atom. But it's also possible to form a related chemical link that instead runs through a nitrogen atom, like those found on amino acids. There were no known enzymes, however, that catalyze these reactions. So, the researchers decided to test whether any existing enzymes could be induced to do something they don't normally do. [...]

Overall, the system they develop is remarkably flexible, able to incorporate a huge range of chemicals into a polymer. This should allow them to tune the resulting plastic across a wide range of properties. And, considering the bonds were formed via enzyme, the resulting polymer will almost certainly be biodegradable. There are, however, some negatives. The process doesn't allow complete control over what gets incorporated into the polymer. You can bias it toward a specific mix of amino acids or other chemicals, but you can't entirely stop the enzyme from incorporating random chemicals from the cell's metabolism into the polymer at some level. There's also the issue of purifying the polymer from all the rest of the cell components before incorporating it into manufacturing. Production is also relatively slow compared to large-scale industrial production. The findings have been published in the journal Nature Chemical Biology.

Damaged corneas were repaired at a Harvard teaching hospital in a unique clinical trial, reports New Atlas: Since it's on the frontline of potential hazards from the outside world, the cornea features a population of limbal epithelial stem cells, which repair minor damage to keep the surface smooth and functional... The new study, conducted by scientists at Massachusetts Eye and Ear, investigated a new treatment called cultivated autologous limbal epithelial cells (CALEC). This involves removing stem cells from a patient's uninjured eye, growing their population in the lab for a few weeks, then surgically transplanting them into the injured eye.

The phase 1/2 trial recruited 14 patients to undergo the procedure, and followed them for 18 months afterwards... By the first checkup at three months, the corneas of seven (50%) of the participants had been completely restored. By the 12-month mark, that number had increased to 11 (79%) patients. Two other participants met the definition for partial success, so the team claims an overall success rate of 92% for CALEC.

An anonymous reader quotes a report from The Guardian: Many of us have been guilty of binning a mushy, overripe banana -- but now scientists say they have a solution with the launch of a genetically engineered non-browning banana. The product is the latest in a series of gene-edited fruits and vegetables designed to have a longer shelf life. Scientists say the technology is emerging as a powerful new weapon against food waste, which occurs globally on an epic scale. The banana, developed by Tropic, a biotech company based in Norwich, is said to remain fresh and yellow for 12 hours after being peeled and is less susceptible to turning brown when bumped during harvesting and transportation.

The company has also developed a slow-ripening banana that has been approved in several countries, which it plans to launch later in the year. Other research teams are working on lettuce that wilts more slowly, bruise-resistant apples and potatoes and identifying the genes that determine how quickly grapes and blueberries shrivel. [...] The company worked out how to disable a gene responsible for the production of an enzyme called polyphenol oxidase, which causes browning. The same gene is silenced in Arctic apples, a genetically modified variety, which has been sold in the US since 2017, and blocking the production of polyphenol oxidase has been shown to work in tomatoes, melon, kiwifruits and mushrooms. In the bananas, Tropic made precise changes to existing genes without introducing foreign genetic material. The report notes that an estimated 33% of the produce that is harvested worldwide is never consumed due to the short shelf-life of many fruit and vegetable products. Bananas are among the most thrown-away foods, with some 5 billion bananas tossed in the U.S. each year.

Britain, the birthplace of the Industrial Revolution, now suffers from its opposite: profound energy shortages and deep affordability crises [non-paywalled link]. A new report titled "Foundations" identifies the root cause -- "it is difficult to build almost anything, anywhere" in the UK.

Housing exemplifies this malaise. Since the 1990s, homeownership among young British workers has halved while housing prices doubled. The 1947 Town and Country Planning Act effectively nationalized development rights, requiring special permission for new construction and establishing restrictive "green belts." Despite Margaret Thatcher's market reforms, British house-building never recovered.

This constrictive policy has stymied potential growth beyond housing, Atlantic reports. Cambridge remains a small city despite biotech breakthroughs that might have transformed it into a major hub. Transit infrastructure languishes -- Leeds is Europe's largest city without a metro system. Energy production has collapsed, with per capita electricity generation now roughly one-third of America's.

Britain faces a self-imposed scarcity crisis. Environmental regulations, while beneficial, created a one-way system where lawsuits easily block development. As co-author Sam Bowman summarized: "Europe has an energy problem; the Anglosphere has a housing problem; Britain has both." The solution requires comprehensive reform-- overhauling the planning system, reducing anti-growth litigation, and encouraging energy production to unlock what the private sector "already wants to do."

San Francisco-based biotech startup Loyal says a drug it developed to increase dogs' lifespan "has passed a significant milestone on the way to regulatory approval," reports the Washington Post: The Food and Drug Administration certified the daily pill as having a "reasonable expectation of effectiveness" at extending senior dogs' lifespans. The regulator's Center for Veterinary Medicine still has to certify that the drug is safe and that Loyal can manufacture it at scale before vets can prescribe the pill to dogs 10 years or older that weigh 14 pounds or more. Loyal's CEO, Celine Halioua, estimates that the process should be complete by the end of 2025 and called the FDA's initial recognition "a key step" to extending dogs' lives...

In the past decade, a subculture of tech entrepreneurship has focused on helping people stave off death, hawking custom-made dietary supplements and $2,500 full-body MRIs and investing in the development of antiaging drugs, among many other efforts. According to data firm Pitchbook, about $900 million in venture capital has been poured into antiaging and longevity start-ups in the past 12 months. Loyal has raised more than $150 million in venture funding since its 2019 founding to develop lifespan-extending drugs initially focused on canines.

Launching veterinary drugs is in some ways easier than winning approval for human treatments. Because dogs and humans have evolved alongside one another, Halioua hopes to eventually apply her findings about pets to help prolong their owners' lives. "If we can successfully delay the onset and severity of age-related diseases in dogs, it's extremely compelling evidence that it will also do that in humans," Halioua said. The biological processes of aging unfold faster in dogs because they live such short lives, she said, helping researchers and entrepreneurs probe how they work.
"Loyal's pill is a result of research into how to mimic the life-extending benefit of caloric restriction without the appetite suppression," according to the article, "and without the need for an owner to restrict their dog's food.

"The drug aims to improve a dog's metabolic fitness, or the body's ability to convert nutrients into energy and regulate hormones, which declines in humans and canines with age..."

"Elizabeth Holmes' fraud conviction has been upheld by a federal appellate panel," writes Slashdot reader ClickOnThis. MSNBC reports: A three-judge panel of the 9th U.S. Circuit Court of Appeals on Monday affirmed the convictions, sentences and nine-figure restitution ordered against both Holmes and Theranos president, Ramesh "Sunny" Balwani. [...] Theranos was supposedly going to revolutionize medical laboratory testing with the ability to run fast, accurate and affordable tests with just a drop of blood from a finger prick. "But the vision sold by Holmes and Balwani was nothing more than a mirage," 9th Circuit Judge Jacqueline H. Nguyen wrote (PDF) for the panel, adding that the "grandiose achievements touted by Holmes and Balwani were half-truths and outright lies."

Holmes was convicted of crimes related to fraud against investors while the jury acquitted her or hung on other counts. Balwani was convicted on all counts at his trial. The federal panel rejected a slew of arguments from both defendants, including that their trials featured improper testimony from Theranos employees. While the ruling is a major setback for the defendants, they can further appeal to a fuller panel of 9th Circuit judges and the Supreme Court, which generally has broad discretion over whether to accept cases for review.